171 related articles for article (PubMed ID: 19392783)
1. New developments in the antiviral treatment of hepatitis C.
de Bruijne J; Weegink CJ; Jansen PL; Reesink HW
Vox Sang; 2009 Jul; 97(1):1-12. PubMed ID: 19392783
[TBL] [Abstract][Full Text] [Related]
2. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
Michielsen P; Ho E; Francque S
Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
[TBL] [Abstract][Full Text] [Related]
3. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
[TBL] [Abstract][Full Text] [Related]
5. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.
Tada T; Toyoda H; Kumada T; Kurisu A; Sugiyama A; Akita T; Ohisa M; Aikata H; Miki D; Chayama K; Tanaka J
J Viral Hepat; 2021 Mar; 28(3):538-547. PubMed ID: 33215790
[TBL] [Abstract][Full Text] [Related]
6. Modelling the impact of improving screening and treatment of chronic hepatitis C virus infection on future hepatocellular carcinoma rates and liver-related mortality.
Cramp ME; Rosenberg WM; Ryder SD; Blach S; Parkes J
BMC Gastroenterol; 2014 Aug; 14():137. PubMed ID: 25100159
[TBL] [Abstract][Full Text] [Related]
7. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
8. [Hepatitis C].
Moradpour D; Blum HE
Ther Umsch; 2004 Aug; 61(8):493-8. PubMed ID: 15457965
[TBL] [Abstract][Full Text] [Related]
9. [Effects of IFN therapy on incidence of hepatocellular carcinoma in HCV positive cirrhosis].
Nishiguchi S; Kubo S; Shiomi S
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):600-4. PubMed ID: 15359868
[No Abstract] [Full Text] [Related]
10. Epidemiology and natural history of hepatitis C virus infection among children and young people.
Modin L; Arshad A; Wilkes B; Benselin J; Lloyd C; Irving WL; Kelly DA
J Hepatol; 2019 Mar; 70(3):371-378. PubMed ID: 30496763
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and treatment of chronic hepatitis C. Practical recommendations and new developments].
Niederau C
Med Klin (Munich); 2001 Oct; 96(10):599-607. PubMed ID: 11715332
[TBL] [Abstract][Full Text] [Related]
12. Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.
Floreani A; Baldo V; Rizzotto ER; Carderi I; Baldovin T; Minola E
J Clin Gastroenterol; 2008 Jul; 42(6):734-7. PubMed ID: 18285717
[TBL] [Abstract][Full Text] [Related]
13. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
14. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
15. New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.
Tong J; Wang YW; Lu YA
J Zhejiang Univ Sci B; 2012 Jan; 13(1):56-82. PubMed ID: 22205621
[TBL] [Abstract][Full Text] [Related]
16. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
[TBL] [Abstract][Full Text] [Related]
17. The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?
Blanco JR; Rivero-Juárez A
Expert Rev Anti Infect Ther; 2016 Nov; 14(11):993-996. PubMed ID: 27686837
[No Abstract] [Full Text] [Related]
18. Reply to: 'Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan'.
Semmler G; Mandorfer M
J Hepatol; 2022 Aug; 77(2):571-572. PubMed ID: 35526785
[No Abstract] [Full Text] [Related]
19. Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection.
Martinez MA; Franco S
Adv Exp Med Biol; 2021; 1322():139-157. PubMed ID: 34258740
[TBL] [Abstract][Full Text] [Related]
20. Update on hepatitis C: epidemiology, treatment and resistance to antiviral therapies.
Ness E; Kowdley KV
Minerva Gastroenterol Dietol; 2015 Sep; 61(3):145-58. PubMed ID: 25990619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]